RxDoctor Payments Data

Molly Urton

Nurse Practitioner · Harrisonville, MONPI 1225576572

Payments from drug & device makers

$2,096in general payments, 2019–2025

Across 118 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$627
  • Organogenesis Inc.$519
  • AstraZeneca$192
  • Novo Nordisk$110
  • Smith+Nephew$77
  • Lilly USA, LLC$72
  • plus $499 from 16 others

What the payments were for

  • Food & beverage$2,096100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,096 in reported general payments places this provider in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$15,543
Medicare patients
62
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide30$40,417
OzempicSemaglutide12$28,299
JardianceEmpagliflozin13$9,741
VascepaIcosapent Ethyl12$6,276
SymbicortBudesonide/Formoterol Fumarate18$4,282
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$3,053
Duloxetine Hcl34$1,763
Metformin Hcl22$1,743
Gabapentin53$1,570
Levothyroxine Sodium126$1,398
Omeprazole55$1,241
Atorvastatin Calcium134$1,205
Losartan Potassium108$978
Potassium Chloride28$820
Amlodipine Besylate119$809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$72$40,41730 claims
Novo NordiskOzempic$110$28,29912 claims
AstraZenecaSymbicort$192$4,28218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Harrisonville

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →